|
1
|
Hauptman N and Glavač D: Long non-coding
RNA in cancer. Int J Mol Sci. 14:4655–4669. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kornienko AE, Guenzl PM, Barlow DP and
Pauler FM: Gene regulation by the act of long non-coding RNA
transcription. BMC Biol. 11:592013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kunej T, Obsteter J, Pogacar Z, Horvat S
and Calin GA: The decalog of long non-coding RNA involvement in
cancer diagnosis and monitoring. Crit Rev Clin Lab Sci. 51:344–357.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maass PG, Luft FC and Bähring S: Long
non-coding RNA in health and disease. J Mol Med (Berl). 92:337–346.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang GY, Zhu YY and Zhang YQ: The
functional role of long non-coding RNA in digestive system
carcinomas. Bull Cancer. 101:E27–E31. 2014.PubMed/NCBI
|
|
6
|
Song X, Cao G, Jing L, Lin S, Wang X,
Zhang J, Wang M, Liu W and Lv C: Analysing the relationship between
lncRNA and protein-coding gene and the role of lncRNA as ceRNA in
pulmonary fibrosis. J Cell Mol Med. 18:991–1003. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guttman M, Amit I, Garber M, French C, Lin
MF, Feldser D, Huarte M, Zuk O, Carey BW, Cassady JP, et al:
Chromatin signature reveals over a thousand highly conserved large
non-coding RNAs in mammals. Nature. 458:223–227. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lancaster JM, Dressman HK, Whitaker RS,
Havrilesky L, Gray J, Marks JR, Nevins JR and Berchuck A: Gene
expression patterns that characterize advanced stage serous ovarian
cancers. J Soc Gynecol Investig. 11:51–59. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Popescu NC and Zimonjic DB:
Chromosome-mediated alterations of the MYC gene in human cancer. J
Cell Mol Med. 6:151–159. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Takahashi Y, Sawada G, Kurashige J, Uchi
R, Matsumura T, Ueo H, Takano Y, Eguchi H, Sudo T, Sugimachi K, et
al: Amplification of PVT-1 is involved in poor prognosis via
apoptosis inhibition in colorectal cancers. Br J Cancer.
110:164–171. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ghesquières H, Larrabee BR, Casasnovas O,
Maurer MJ, McKay JD, Ansell SM, Montgomery D, Asmann YW, Farrell K,
Verney A, et al: A susceptibility locus for classical Hodgkin
lymphoma at 8q24 near MYC/PVT1 predicts patient outcome in two
independent cohorts. Br J Haematol. Sep 9–2016.(Epub ahead of
print). doi: 10.1111/bjh.14306. View Article : Google Scholar
|
|
12
|
Guan Y, Kuo WL, Stilwell JL, Takano H,
Lapuk AV, Fridlyand J, Mao JH, Yu M, Miller MA, Santos JL, et al:
Amplification of PVT1 contributes to the pathophysiology of ovarian
and breast cancer. Clin Cancer Res. 13:5745–5755. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li W, Wang H, Zhang J, Zhai L, Chen W and
Zhao C: miR-199a-5p regulates β1 integrin through Ets-1 to suppress
invasion in breast cancer. Cancer Sci. 107:916–923. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang F, Yuan JH, Wang SB, Yang F, Yuan SX,
Ye C, Yang N, Zhou WP, Li WL, Li W, et al: Oncofetal long noncoding
RNA PVT1 promotes proliferation and stem cell-like property of
hepatocellular carcinoma cells by stabilizing NOP2. Hepatology.
60:1278–1290. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kong R, Zhang EB, Yin DD, You LH, Xu TP,
Chen WM, Xia R, Wan L, Sun M, Wang ZX, et al: Long noncoding RNA
PVT1 indicates a poor prognosis of gastric cancer and promotes cell
proliferation through epigenetically regulating p15 and p16. Mol
Cancer. 14:822015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mu C, Jia P, Yan Z, Liu X, Li X and Liu H:
Quercetin induces cell cycle G1 arrest through elevating Cdk
inhibitors p21 and p27 in human hepatoma cell line (HepG2). Methods
Find Exp Clin Pharmacol. 29:179–183. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang XQ, Yang CY, Rao XF and Xiong JP:
Plumbagin shows anti-cancer activity in human breast cancer cells
by the upregulation of p53 and p21 and suppression of G1 cell cycle
regulators. Eur J Gynaecol Oncol. 37:30–35. 2016.PubMed/NCBI
|
|
18
|
Liu W, Dai Q, Lu N, Wei L, Ha J, Rong J,
Mu R, You Q, Li Z and Guo Q: LYG-202 inhibits the proliferation of
human colorectal carcinoma HCT-116 cells through induction of G1/S
cell cycle arrest and apoptosis via p53 and p21WAF1/Cip1
expression. Biochem Cell Biol. 89:287–298. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Eng C: Circulating DNA biomarkers: A
primer for metastatic colorectal cancer? Lancet Oncol. 16:878–879.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hällström TM, Puhka M and Kallioniemi O:
Circulating tumor DNA in early-stage breast cancer: Personalized
biomarkers for occult metastatic disease and risk of relapse? EMBO
Mol Med. 7:994–995. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fackler MJ, Bujanda Z Lopez, Umbricht C,
Teo WW, Cho S, Zhang Z, Visvanathan K, Jeter S, Argani P, Wang C,
et al: Novel methylated biomarkers and a robust assay to detect
circulating tumor DNA in metastatic breast cancer. Cancer Res.
74:2160–2170. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schwarzenbach H and Pantel K: Circulating
DNA as biomarker in breast cancer. Breast Cancer Res. 17:1362015.
View Article : Google Scholar : PubMed/NCBI
|
